ACES logo

Ascelia Pharma BATS-CHIXE:ACES Stock Report

Last Price

SEK 20.55

Market Cap

SEK 672.7m

7D

0%

1Y

n/a

Updated

31 Aug, 2022

Data

Company Financials +

Ascelia Pharma AB (publ)

BATS-CHIXE:ACES Stock Report

Market Cap: SEK 672.7m

ACES Stock Overview

A biotech company, focuses on orphan oncology treatments in Sweden. More details

ACES fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Ascelia Pharma AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ascelia Pharma
Historical stock prices
Current Share PriceSEK 20.55
52 Week HighSEK 20.55
52 Week LowSEK 20.45
Beta0.74
11 Month Change0%
3 Month Changen/a
1 Year Changen/a
33 Year Changen/a
5 Year Changen/a
Change since IPO9.60%

Recent News & Updates

Recent updates

Shareholder Returns

ACESGB BiotechsGB Market
7D0%-5.2%0.8%
1Yn/a-20.1%6.6%

Return vs Industry: Insufficient data to determine how ACES performed against the UK Biotechs industry.

Return vs Market: Insufficient data to determine how ACES performed against the UK Market.

Price Volatility

Is ACES's price volatile compared to industry and market?
ACES volatility
ACES Average Weekly Movementn/a
Biotechs Industry Average Movement9.6%
Market Average Movement4.7%
10% most volatile stocks in GB Market10.3%
10% least volatile stocks in GB Market2.6%

Stable Share Price: ACES has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine ACES's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
199921Magnus Corfitzenwww.ascelia.com

Ascelia Pharma AB (publ), a biotech company, operates as an oncology-focused orphan drug development company in Sweden. It is developing Mangoral, a novel non-gadolinium contrast agent, which is in Phase 3 for use in MRI-scans of the liver; and Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 for the treatment of gastric cancer. It has a clinical collaboration agreement with Taiho Oncology, Inc. for the development of Oncoral in combination with LONSURF.

Ascelia Pharma AB (publ) Fundamentals Summary

How do Ascelia Pharma's earnings and revenue compare to its market cap?
ACES fundamental statistics
Market capSEK 672.69m
Earnings (TTM)-SEK 115.48m
Revenue (TTM)n/a

0.0x

P/S Ratio

-5.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ACES income statement (TTM)
RevenueSEK 0
Cost of RevenueSEK 0
Gross ProfitSEK 0
Other ExpensesSEK 115.48m
Earnings-SEK 115.48m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Nov 04, 2022

Earnings per share (EPS)-3.43
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ACES perform over the long term?

See historical performance and comparison